Nephrosphere

As expected, the realities of dual treatment are challenging.

“Forty-five percent of CKD stage 3–5 patients did not tolerate dual RAS blockade with 20 mg enalapril and 16 mg candesartan daily, primarily due to loss of renal function or hypotension.”

via Feasibility of combined treatment with enalapril and candesartan in advanced chronic kidney disease — Frimodt-Møller et al. 25 3: 842 — Nephrology Dialysis Transplantation.